drugset / Trial / NCT00729950
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
Timeline
- Start
- 2003-07
- Primary completion
- 2005-10
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 2.8 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 7.5 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 20 mg/kg | — |